August 5, 2022

Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis

July 27, 2022

Myovant Sciences Announces Corporate Updates and Financial Results for First Fiscal Quarter 2022

July 18, 2022

Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08

July 13, 2022

Myovant Sciences to Host First Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m. Eastern Time on July 27, 2022

June 17, 2022

Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain

June 16, 2022

Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08

June 3, 2022

Myovant Sciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

June 2, 2022

Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®

May 10, 2022

Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2022

May 9, 2022

Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe